Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.

This study found a relatively low prevalence of cutaneous reactions in chronic hepatitis C patients treated with peginterferon alfa and ribavirin, with reactions correlated to age and treatment duration.

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.

This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.

In this study, pegylated interferon alpha therapy was independently associated with more severe hair loss, particularly acute telogen effluvium, in chronic hepatitis B patients with alopecia, compared to nucleos(t)ide analog therapy, emphasizing the importance of monitoring and counseling, especially for younger female patients.

This case study reports the first extensively interpreted instance of dystrophic telogen effluvium potentially linked to pegylated interferon and ribavirin therapy for chronic hepatitis C, characterized through clinical and trichogram analysis.

In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.

This case report detailed alopecia universalis developing shortly after hepatitis C treatment with peg-interferon, ribavirin, and telaprevir, suggesting potential immune-related links between interferon treatment and alopecia areata.

This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.

In this study, a novel biofilm-dispersing wound gel did not interfere with healing and may enhance it by reducing inflammation in murine models with full-thickness skin wounds.

This case study suggests that treatment with Pil-Food, intended for hair loss prevention, may have triggered postinfantile giant cell hepatitis with autoimmune characteristics, which showed a rapid and effective response to corticosteroid therapy.

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.

This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.

In this study, researchers examined chronic hepatitis B patients and found that those undergoing interferon therapy reported higher quality of life than those on non-antiviral or nucleoside/nucleotide analogue treatments, despite potential side effects.

This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.

This review discusses the involvement of type I interferons in skin autoimmune and inflammatory diseases but reports no new clinical results.

This study reported that while lichen planus was not significantly linked to hepatitis C virus infection, pruritus, dry skin, and hair loss were more common in HCV patients post-interferon treatment.

This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.

In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.

The study found that silencing the gene p16INK4a in dermal papilla cells promotes their growth and aggregative behavior, suggesting a potential therapeutic target for androgenetic alopecia.

The researchers reported that silencing the NtNCED3-2 gene in tobacco reduced ABA content and drought tolerance, inhibited root and leaf development, and decreased photosynthetic ability due to altered isoprenoid metabolism.

This review covers various aspects of hair biology, pigmentation, and development, focusing on genetic and biochemical modulation of hair follicle components but reports no new findings.

New materials and methods could improve skin healing and reduce scarring.

This review discusses advancements in artificial skin for wound treatment and reports no new clinical findings; the authors highlight the potential of new biomaterials to enhance future skin replacement therapies.